– USA, MA – OvaScience (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald F. Stock, Ph.D., has officially assumed the role of President and Chief Executive Officer, completing a planned leadership transition from Chief Executive Officer-Elect. Dr. Stock succeeds OvaScience Co-founder Michelle Dipp, M.D., Ph.D., who will now serve as Executive Chair of the Board of Directors.
“In just four short years, OvaScience has advanced a transformative fertility treatment —AUGMENT— from concept to clinic to commercial availability, while building a strong pipeline of innovations for the future,” said Dr. Stock. “Moving forward, we will align our resources to focus on expanding access to AUGMENT in Canada and Japan, bringing patient engagement to the center of our operating model and accruing additional real world data to demonstrate the value and clinical benefit of our treatments. We have put a remarkable team in place to achieve these objectives and to position OvaScience for near- and long-term growth.”
Dr. Stock has served on the OvaScience Board of Directors since 2013 and brings extensive experience globally scaling operations and commercialization for innovative, emerging growth healthcare companies. Most recently, Dr. Stock served as President and CEO of Sweden-based ArjoHuntleigh, a leading acute and long-term care equipment company with global revenues of approximately $1 billion. At ArjoHuntleigh, he led the growth turnaround of the company through a renewal of the company’s portfolio and an increased focus on emerging markets. Dr. Stock also served as Executive Vice President, Extend Care Business Area, of Getinge Group, the publicly listed principal owner of ArjoHuntleigh.
Before joining ArjoHuntleigh and Getinge Group, Dr. Stock was the CEO of Grünenthal, an international research-based pharmaceutical company headquartered in Germany, where he led the global transformation to focus on innovative pain medications and expand in Latin America. While at Grünenthal, he grew revenues in Europe and the U.S. with the launch of Palexia / Nucynta (Tapentadol). Prior to joining Grünenthal in 2009, Dr. Stock was Chairman and Managing Director at DePuy, the Orthopedics Division of Johnson & Johnson. Previously, he led corporate divisions of the Roche Group including Senior Vice President of the Global Near Patient Testing business. Dr. Stock holds a Ph.D. in Inorganic Chemistry from Ruprecht-Karls-University of Heidelberg, Germany.
About OvaScience
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a study with the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
